Clinical Trials Arena on MSN

Gilead’s HIV single-pill combo meets primary endpoints in pivotal trial

Gilead has become a significant name in the HIV landscape after its twice-yearly PrEP treatment Yeztugo touted 99.9% efficacy ...

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The ...

Gilead hits late-stage trial win for new single-tablet HIV therapy

Gilead (GILD) stock gains as the company's new single-tablet HIV regimen is proven as effective as multi-tablet therapies in ...

Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.
TipRanks on MSN

Gilead announces ARTISTRY-1 trial meets primary endpoint

Gilead (GILD) announced topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with ...
The Manila Times

Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update

WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, ...
Technology Networks

An Introduction to Bioinformatics, Bioinformatics Tools and Applications

This article introduces the field of bioinformatics and its importance as a cornerstone of biological research, as well as ...
Healio

Oral PCSK9 inhibitor lowers LDL by up to 60%

A novel once-daily oral PCSK9 inhibitor lowered LDL by up to 60% at 24 weeks in patients with heart disease or at high risk ...

Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call Transcript

Q3 2025 Earnings Call November 10, 2025 8:30 AM ESTCompany ParticipantsKate Rausch - Head of Investor RelationsPaul Bolno ...
Le Lézard

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

Ionis Pharmaceuticals, Inc. today announced positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). The studies met the primary ...

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...
Le Lézard

Datavault AI Inc. (NASDAQ: DVLT) Issues Investor Update Highlighting Continued Revenue Growth, Strategic Partnerships, and Global Expansion

IBN ? Datavault AI Inc. , a leader in data monetization, credentialing, and digital engagement technologies, today released an Investor Update detailing key developments across its financial ...